Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences

Rhea-AI Summary

Ocular Therapeutix (NASDAQ: OCUL) has announced its participation in key December investor and scientific conferences. The company will present at the Piper Sandler 36th Annual Healthcare Conference with a fireside chat on December 3rd, 2024, featuring CEO Pravin U. Dugel. Additionally, the company will have a significant presence at FLORetina ICOOR 2024 in Florence, Italy, with multiple presentations scheduled between December 5-7, 2024.

The presentations will focus on their OTX-TKI treatment, including 48-week results from the HELIOS Phase I Trial for non-proliferative diabetic retinopathy, and discussions on TKIs in retinal disease management. Multiple sessions will feature presentations by leading medical experts including Dr. Dilsher S. Dhoot and Dr. Diana V. Do.

News Market Reaction – OCUL

+7.26%

1 alert

+7.26% News Effect

On the day this news was published, OCUL gained 7.26%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

BEDFORD, Mass. , Nov. 26, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced participation in several investor and scientific conferences being held in December.

Piper Sandler 36^th Annual Healthcare Conference
Fireside Chat Date: Tuesday, December 3rd, 2024
Fireside Chat Time: 1:30 PM ET
Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO
Location: New York City, NY

The live fireside chat can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page.

FLORetina ICOOR 2024
Florence, Italy

• 48-week Results from the HELIOS Phase I Trial Evaluating Intravitreal OTX-TKI for Non-proliferative Diabetic Retinopathy
  Session: Highlighted New Drugs DME
  Presentation Date/Time: Thursday, December 5, 2024, 1:33 – 1:36PM CET
  Presenter: Dilsher S. Dhoot, MD

• OTX-TKI – The Evolution of Optimized AXPAXLI (AUS >> US >> SOL-1)
  Session: Retina Futura 1: Wet Age-Related Macular Degeneration (wAMD): Emerging Therapies and Clinical Updates
  Presentation Date/Time Friday, December 6, 2024, 11:29 – 11:33AM CET
  Presenter: Diana V. Do, MD

• HELIOS: Phase 1 SAFETY Study of AXPAXLI in NPDR
  Session: Retina Futura 2: Diabetic Retinal Diseases and Retinal Detachment
  Presentation Date/Time: Friday, December 6, 2024, 2:12 – 2:16PM CET
  Presenter: Dilsher S. Dhoot, MD

• TKIs in the Future of Retinal Disease Management
  Session: Afternoon Symposium
  Session Date/Time: Saturday, December 7, 2024, 3:30 – 4:30 PM CET

About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions. AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI), Ocular’s product candidate for retinal disease, is based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).

Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA^®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, and in its product candidate PAXTRAVA™ (travoprost intracameral implant or OTX-TIC), which is currently in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.

Follow the Company on its website, LinkedIn, or X.

The Ocular Therapeutix logo and DEXTENZA^® are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.

Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com

FAQ

When is Ocular Therapeutix (OCUL) presenting at the Piper Sandler Healthcare Conference?

Ocular Therapeutix will present at the Piper Sandler Healthcare Conference on Tuesday, December 3rd, 2024, at 1:30 PM ET in New York City.

What clinical trial results will OCUL present at FLORetina ICOOR 2024?

OCUL will present 48-week results from the HELIOS Phase I Trial evaluating intravitreal OTX-TKI for non-proliferative diabetic retinopathy on December 5, 2024.

How many presentations will Ocular Therapeutix make at FLORetina ICOOR 2024?

Ocular Therapeutix will make four presentations at FLORetina ICOOR 2024 in Florence, Italy, between December 5-7, 2024, covering various aspects of OTX-TKI and retinal disease management.